George Carlone
Overview
Explore the profile of George Carlone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
850
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rajam G, Stella M, Kim E, Paulos S, Boccadifuoco G, Serino L, et al.
mSphere
. 2019 Jun;
4(3).
PMID: 31189561
No abstract available.
2.
Rajam G, Carlone G, Kim E, Choi J, Paulos S, Park S, et al.
Biologicals
. 2018 Nov;
57:9-20.
PMID: 30458978
Despite wide spread vaccination, the public health burden of pertussis remains substantial. Current acellular pertussis vaccines comprise upto five Bordetella pertussis (Bp) antigens. Performing an ELISA to quantify antibody for...
3.
Rajam G, Stella M, Kim E, Paulos S, Boccadifuoco G, Serino L, et al.
mSphere
. 2017 Nov;
2(6).
PMID: 29152576
is the most common cause of bacterial meningitis in children and young adults worldwide. A 4-component vaccine against serogroup B (MenB) disease (MenB-4C [Bexsero]; GSK) combining factor H binding protein...
4.
Holme D, Findlow H, Sow S, Idoko O, Preziosi M, Carlone G, et al.
Clin Infect Dis
. 2015 Nov;
61 Suppl 5:S563-9.
PMID: 26553689
Background: A group A meningococcal conjugate vaccine, PsA-TT, was licensed in 2010 and was previously studied in a phase 2 clinical trial to evaluate its safety and immunogenicity in African...
5.
Price G, Hollander A, Plikaytis B, Mocca B, Carlone G, Findlow H, et al.
Clin Infect Dis
. 2015 Nov;
61 Suppl 5:S554-62.
PMID: 26553688
Background: PsA-TT (MenAfriVac) is a conjugated polysaccharide vaccine developed to eliminate group A meningococcal disease in Africa. Vaccination of African study participants with 1 dose of PsA-TT led to the...
6.
Diallo A, Sow S, Idoko O, Hirve S, Findlow H, Preziosi M, et al.
Clin Infect Dis
. 2015 Nov;
61 Suppl 5:S521-30.
PMID: 26553684
Background: Mass vaccination campaigns of the population aged 1-29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in...
7.
Tapia M, Findlow H, Idoko O, Preziosi M, Kulkarni P, Enwere G, et al.
Clin Infect Dis
. 2015 Nov;
61 Suppl 5:S514-20.
PMID: 26553683
Background: Following mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to group A meningococci has nearly disappeared. Antibody persistence in...
8.
Idoko O, Okolo S, Plikaytis B, Akinsola A, Viviani S, Borrow R, et al.
Vaccine
. 2014 May;
32(33):4220-7.
PMID: 24863486
Major epidemics of serogroup A meningococcal meningitis continue to affect the African meningitis belt. The development of an affordable conjugate vaccine against the disease became a priority for World Health...
9.
Hirve S, Bavdekar A, Pandit A, Juvekar S, Patil M, Preziosi M, et al.
Vaccine
. 2012 Aug;
30(45):6456-60.
PMID: 22898557
This study compares the immunogenicity and safety of a single dose of a new meningococcal A conjugate vaccine (PsA-TT, MenAfriVac™, Serum Institute of India Ltd., Pune) against the meningococcal group...
10.
A gel-free proteomic-based method for the characterization of Bordetella pertussis clinical isolates
Williamson Y, Moura H, Simmons K, Whitmon J, Melnick N, Rees J, et al.
J Microbiol Methods
. 2012 Apr;
90(2):119-33.
PMID: 22537821
Bordetella pertussis (Bp) is the etiologic agent of pertussis or whooping cough, a highly contagious respiratory disease occurring primarily in infants and young children. Although vaccine preventable, pertussis cases have...